GO:0030109 HLA-B specific inhibitory MHC class I receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030109 describes a molecular function in which a receptor binds an HLA-B class I molecule and delivers an inhibitory signal to a lymphocyte.
• The best-characterized receptors carrying this activity are the leukocyte Ig-like receptor (LILR) family, especially LILRB1/ILT2 and LILRB2/ILT4, and certain killer cell Ig-like receptors (KIRs).
• Recognition depends on HLA-B allelic sequence and conformation, including the Bw4/Bw6 motif and intracellular cysteine residues in the MHC class I tail.
• This inhibitory axis tunes natural killer (NK) cell and T cell activation thresholds, shaping antiviral and antitumor immunity.
• HLA-B-specific inhibitory signaling is relevant to transplantation, autoimmune disease, drug hypersensitivity and cancer immunotherapy.
• CRISPR knockout, point-mutation, knock-in and overexpression models allow causal dissection of receptor-ligand pairs in this pathway.
Description
GO:0030109, HLA-B specific inhibitory MHC class I receptor activity, is a molecular function in which a receptor combines with an MHC class I molecule of the HLA-B subclass to mediate signaling that inhibits activation of a lymphocyte. This activity sits at the interface between adaptive and innate immunity: HLA-B molecules present peptide to T cells, but they also engage inhibitory receptors on natural killer (NK) cells and T lymphocytes to set activation thresholds. The existence of MHC class I-specific inhibitory receptors on human NK and T cells was established in the 1990s, when it became clear that these receptors survey class I expression and deliver negative signals. Because HLA-B is among the most polymorphic human genes, the strength of this inhibitory interaction varies between individuals and populations. Understanding GO:0030109 therefore matters for immunology, transplantation, infectious disease and cancer immunotherapy. Researchers study it to define how allelic variation in HLA-B and its receptors changes lymphocyte responsiveness, and to engineer cells or receptors with predictable inhibitory behavior.
HLA-B specific inhibitory MHC class I receptor activity At A Glance
| GO ID | GO:0030109 |
|---|---|
| GO term | HLA-B specific inhibitory MHC class I receptor activity |
| Ontology | molecular_function |
| Synonym | None listed in QuickGO |
| Definition | Combining with a MHC class I molecule of the HLA-B subclass to mediate signaling that inhibits activation of a lymphocyte |
| Major function | Inhibitory recognition of HLA-B by lymphocyte receptors, dampening lymphocyte activation |
| Representative receptors | LILRB1/ILT2, LILRB2/ILT4, inhibitory KIRs such as KIR3DL |
| Ligand subclass | MHC class I, HLA-B subclass, including Bw4/Bw6 motifs |
| Cell types | NK cells and T lymphocytes |
What Is GO:0030109?
In plain terms, GO:0030109 is the activity of a receptor that grabs an HLA-B molecule and sends a 'do not attack' signal into a lymphocyte. The official definition is: combining with a MHC class I molecule of the HLA-B subclass to mediate signaling that inhibits activation of a lymphocyte. It is a molecular_function term, so it describes what the receptor does at the molecular level rather than a whole pathway or cellular location. The HLA-B subclass restriction is important: the same receptor may bind other class I molecules, but this term specifically covers engagement of HLA-B and the resulting inhibitory signal.
Why Is HLA-B specific inhibitory MHC class I receptor activity Important in Cell Biology?
GO:0030109 is important because it defines a checkpoint that prevents lymphocytes from overreacting to healthy cells while still permitting responses to infected or transformed cells. HLA-B is extremely polymorphic, and allelic differences change how strongly it engages inhibitory receptors, which in turn influences NK cell education and T cell responsiveness. This activity has direct clinical echoes: HLA-B-restricted inhibitory recognition is implicated in drug hypersensitivity through HLA class I conjugation, in transplantation and antiviral immunity through NK cell licensing, and in cancer immunotherapy because inhibitory receptor blockade can unleash lymphocyte killing. Studying GO:0030109 helps explain why some individuals mount stronger NK or T cell responses and provides a rationale for engineering receptors or HLA alleles in research models.
• Sets the activation threshold of NK cells and T lymphocytes by delivering inhibitory signals upon HLA-B engagement.
• Explains inter-individual differences in immunity because HLA-B allelic sequence and conformation alter receptor binding.
• Contributes to NK cell education and licensing, shaping antiviral and antitumor competence.
• Is relevant to drug hypersensitivity, where amoxicillin conjugates to HLA class I and interferes with ILT2/LIR-1 signaling.
• Provides a target for cancer immunotherapy strategies that block inhibitory receptors to restore lymphocyte killing.
• Informs transplantation immunology because donor-recipient HLA-B differences affect inhibitory receptor engagement.
• Guides development of HLA-B transgenic and receptor-knockout models for mechanistic studies.
• Links structural features of MHC class I, such as intracellular cysteine residues, to extracellular receptor recognition.
• Supports comparative immunology, since macaque KIR3DL shows degenerate recognition of Bw4 and Bw6 motifs.
• Offers a defined molecular function for CRISPR screens and reporter assays of inhibitory signaling.
Molecular Mechanism of HLA-B specific inhibitory MHC class I receptor activity
HLA-B ligand recognition by inhibitory receptors
In simple terms: The receptor first has to physically bind the HLA-B molecule on another cell.
Inhibitory MHC class I receptors on human NK and T cells were originally defined by their ability to recognize class I molecules and deliver negative signals. For GO:0030109, the ligand is specifically an HLA-B molecule. Binding is sensitive to HLA class I allelic sequence and conformation, meaning that different HLA-B variants are recognized with different affinities. The Bw4 and Bw6 motifs are classic determinants of this recognition, and even macaque KIR3DL can degenerately recognize both motifs, illustrating the importance of motif context. Thus the first step of the activity is a structurally selective receptor-HLA-B interaction.
Inhibitory signal transduction into the lymphocyte
In simple terms: Once bound, the receptor sends a brake signal inside the lymphocyte.
Engagement of MHC class I-specific receptors on NK and T cells mediates signaling that inhibits activation. This is the defining functional consequence of GO:0030109: the receptor is not merely an adhesion molecule but a signal-transducing brake. The inhibitory output depends on the receptor's cytoplasmic signaling machinery, which is why the term is annotated as a molecular function that mediates inhibition of lymphocyte activation. Experimental interference with this signaling, for example by amoxicillin conjugation to HLA class I, can disrupt inhibitory signaling through ILT2/LIR-1/CD85j.
Allelic and conformational control of receptor engagement
In simple terms: Small changes in HLA-B shape or sequence can strengthen or weaken the brake.
HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding, so the same receptor can show different reactivity across HLA-B allotypes. This structural selectivity is central to GO:0030109 because the term is restricted to the HLA-B subclass. Intracellular cysteine residues in the tail of MHC class I proteins are crucial for extracellular recognition by leukocyte Ig-like receptor 1, revealing that ligand conformation, not just the extracellular domain, controls receptor engagement. Population genetics further shows that adaptive admixture of HLA class I allotypes enhanced genetically determined strength of natural killer cells in East Asians, linking allelic variation to functional inhibitory strength.
Integration with lymphocyte activation thresholds
In simple terms: The brake is weighed against activating signals to decide whether the lymphocyte fires.
The molecular function described by GO:0030109 does not act in isolation; it opposes activating signals and thereby sets the threshold for NK and T cell responses. This integration is why the term matters for immune surveillance: inhibitory recognition of HLA-B helps prevent inappropriate lymphocyte activation while preserving responsiveness when class I expression is perturbed. HLA-B*0702 transgenic mice have been used to study human B*0702-restricted CTL epitopes, providing an in vivo context in which HLA-B-specific recognition and lymphocyte function can be dissected.
Regulation by ligand availability and receptor expression
In simple terms: How much HLA-B and how much receptor are present changes the strength of the brake.
Because the activity requires combining with an HLA-B molecule, its magnitude depends on HLA-B surface levels and on receptor expression on the lymphocyte. Changes in HLA class I conformation or trafficking can therefore alter inhibitory signaling even without changes in receptor abundance. This ligand-dependent regulation explains why HLA-B genotype and expression are repeatedly linked to functional differences in NK cells and T cells.
Key Genes Involved in GO:0030109 HLA-B specific inhibitory MHC class I receptor activity
The genes most directly tied to GO:0030109 encode HLA-B itself and the inhibitory receptors that recognize it, together with related MHC class I and receptor family members that define the pathway context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HLA-B | Provides the HLA-B class I ligand for the inhibitory receptor | Central ligand of GO:0030109; allelic variants alter receptor binding |
| LILRB1 (ILT2, LIR-1, CD85j) | Leukocyte Ig-like inhibitory receptor that binds MHC class I including HLA-B | Key receptor for inhibitory signaling; disrupted by amoxicillin conjugation |
| LILRB2 (ILT4, LIR-2) | Leukocyte Ig-like inhibitory receptor of the LILR family | Contributes to class I inhibitory recognition and receptor-binding studies |
| KIR3DL | Killer cell Ig-like receptor with inhibitory function | Recognizes Bw4/Bw6 motifs and informs HLA-B-specific inhibitory recognition |
| KIR3DL1 | Inhibitory KIR recognizing HLA-B Bw4 allotypes | Model receptor for HLA-B-specific inhibition in NK cells |
| KIR3DL2 | Inhibitory KIR family member | Part of the MHC class I-specific receptor repertoire on NK and T cells |
| KIR2DL | Inhibitory KIR family members | Broader context of class I-specific inhibitory receptors |
| B2M | Beta-2-microglobulin, required for MHC class I surface expression | Loss of B2M abolishes class I ligand presentation for inhibitory receptors |
| TAP1 | Peptide transporter for MHC class I loading | Affects HLA-B peptide loading and surface conformation |
| TAP2 | Peptide transporter for MHC class I loading | Affects HLA-B peptide loading and surface conformation |
| HLA-A | Related MHC class I molecule | Comparative ligand for class I-specific inhibitory receptors |
| HLA-C | Related MHC class I molecule | Comparative ligand and KIR recognition context |
| HLA-E | Non-classical MHC class I molecule | Context for class I-specific inhibitory receptor biology |
| LILRA family | Activating relatives of LILR receptors | Contrasts activating versus inhibitory recognition |
| PTPN6 (SHP-1) | Phosphatase recruited by inhibitory receptors | Downstream brake machinery for inhibitory signaling |
| PTPN11 (SHP-2) | Phosphatase involved in inhibitory receptor signaling | Downstream signaling context for lymphocyte inhibition |
| CD3 complex genes | T cell receptor signaling components | Integration of inhibitory signals with T cell activation |
How Is HLA-B specific inhibitory MHC class I receptor activity Regulated?
GO:0030109 is regulated at several levels. Ligand availability matters because the activity requires combining with an HLA-B molecule, so HLA-B surface expression and peptide loading influence inhibitory strength. Ligand conformation matters because intracellular cysteine residues in the MHC class I tail are crucial for extracellular recognition by leukocyte Ig-like receptor 1, showing that the receptor reads structural features beyond the simple presence of HLA-B. Receptor expression and allelic variation matter because HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding. Finally, pharmacological or chemical modification of HLA class I, such as amoxicillin conjugation, can interfere with signaling through the ILT2/LIR-1/CD85j inhibitory receptor, providing an example of extrinsic regulation.
HLA-B specific inhibitory MHC class I receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HLA-B | Drug hypersensitivity and altered inhibitory signaling | HLA-B point-mutation or knock-in cell lines with LILRB1 reporter |
| LILRB1 (ILT2, LIR-1, CD85j) | Disrupted inhibitory signaling in drug reactions | LILRB1 knockout and tagged knock-in lymphocyte models |
| KIR3DL1 | NK cell competence and antiviral immunity | KIR3DL1 knockout NK cell lines with HLA-B Bw4 ligands |
| HLA-B*0702 | Human HLA-B-restricted T cell recognition | HLA-B*0702 transgenic mouse and CRISPR-edited cells |
| B2M | Loss of MHC class I ligand presentation | B2M knockout cells to abolish HLA-B surface expression |
Drug hypersensitivity and altered inhibitory signaling
Amoxicillin conjugates to HLA class I molecules and interferes with signaling through the ILT2/LIR-1/CD85j inhibitory receptor, directly linking chemical modification of HLA class I to disrupted inhibitory signaling. This provides a mechanistic example of how GO:0030109-related recognition can be perturbed in a clinical drug reaction context.
NK cell competence and population differences in immunity
Adaptive admixture of HLA class I allotypes enhanced genetically determined strength of natural killer cells in East Asians, indicating that HLA-B variation shapes functional NK cell capacity. Because GO:0030109 defines inhibitory HLA-B recognition, these population-level differences are expected to influence antiviral and antitumor immunity.
Cancer immunotherapy and inhibitory receptor blockade
MHC class I-specific receptors on human NK and T lymphocytes deliver inhibitory signals that can limit lymphocyte activation. Blocking or modulating this inhibitory axis is a recognized strategy to restore lymphocyte killing in cancer immunotherapy, making GO:0030109 a conceptually important function in immuno-oncology.
Transplantation and HLA-B matching
HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding, so donor-recipient HLA-B differences can change inhibitory receptor engagement. HLA-B transgenic models such as HLA-B*0702 mice allow study of human HLA-B-restricted T cell responses in vivo, which is relevant to transplantation and immune recognition research.
From HLA-B specific inhibitory MHC class I receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of the receptor abolish HLA-B-specific inhibition? | CRISPR knockout of LILRB1 or KIR3DL in NK or T cell lines |
| Which HLA-B residues control receptor engagement? | Point mutation of HLA-B alleles at Bw4/Bw6 or tail cysteine residues |
| Can a specific HLA-B allele reconstitute inhibitory signaling? | Knock-in of HLA-B alleles into class I-deficient cells |
| Where and when does the receptor meet HLA-B? | Tagged knock-in of LILRB1 or HLA-B for imaging and proteomics |
| Does overexpression strengthen the inhibitory brake? | Overexpression of LILRB1 or HLA-B in lymphocyte reporter lines |
| Can chemical modification disrupt the interaction? | Amoxicillin-treated HLA class I cells with ILT2 signaling readouts |
How to Study the HLA-B specific inhibitory MHC class I receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Receptor-ligand binding assay | Direct binding of LILR or KIR to HLA-B | Comparing HLA-B alleles and conformations |
| Inhibitory signaling reporter assay | Strength of negative signal after receptor engagement | Testing ILT2/LIR-1/CD85j pathway disruption |
| NK cell cytotoxicity assay | Inhibition of NK killing by HLA-B recognition | Assessing HLA-B-specific inhibitory function |
| T cell activation assay | Cytokine production or proliferation under inhibitory signals | Dissecting lymphocyte inhibition thresholds |
| Flow cytometry | Surface HLA-B and receptor expression levels | Correlating ligand density with inhibitory strength |
| CRISPR knockout screening | Genes required for HLA-B-specific inhibition | Identifying pathway components in lymphocyte lines |
| Transgenic mouse model | In vivo HLA-B-restricted T cell responses | Studying human HLA-B*0702 recognition |
| Site-directed mutagenesis | Contribution of specific residues to recognition | Mapping Bw4/Bw6 and tail cysteine requirements |
Binding and affinity assays
Receptor-ligand binding assays are used to measure how leukocyte Ig-like receptors engage HLA class I alleles and conformations. Such assays can compare HLA-B variants and Bw4/Bw6 motifs to define the structural rules of GO:0030109.
Inhibitory signaling readouts
Functional readouts of lymphocyte inhibition are needed to confirm that receptor engagement actually transduces a negative signal. These can include reporter systems for ILT2/LIR-1/CD85j signaling and assays that detect disruption by chemical modification of HLA class I.
NK and T cell functional assays
NK cell and T cell activation assays reveal how HLA-B-specific inhibitory recognition changes killing or cytokine production. Population-level differences in NK cell strength associated with HLA class I allotypes can be probed in such assays.
Genetically engineered models
Transgenic and CRISPR-edited models allow causal testing of HLA-B and receptor contributions. HLA-B*0702 transgenic mice, for example, support study of human B*0702-restricted CTL epitopes and recognition.
How CRISPR Can Be Used to Study GO:0030109 HLA-B specific inhibitory MHC class I receptor activity
Knockout
CRISPR knockout of inhibitory receptors such as LILRB1 or KIR3DL removes the brake and tests whether HLA-B-specific inhibition is lost. Knockout of B2M abolishes MHC class I surface expression and provides a ligand-null background for reconstitution experiments.
Point Mutation
Point mutation of HLA-B residues, including Bw4/Bw6 determinants and intracellular tail cysteines, can define which structural features are required for receptor recognition. This is essential for attributing function to specific HLA-B alleles rather than to class I molecules generically.
Knock-in
Knock-in of defined HLA-B alleles into class I-deficient cells or model organisms allows controlled reconstitution of HLA-B-specific inhibitory activity. HLA-B*0702 transgenic systems illustrate how a single human HLA-B allele can be studied in vivo.
Overexpression
Overexpression of LILRB1 or HLA-B can amplify the inhibitory signal and make weak interactions measurable in reporter assays. This approach helps quantify how allelic or conformational changes shift the balance between activation and inhibition.
How EDITGENE Supports HLA-B specific inhibitory MHC class I receptor activity Research
Researchers studying HLA-B specific inhibitory MHC class I receptor activity-related genes often need to determine whether a candidate receptor or HLA-B allele is causally involved in lymphocyte inhibition, rather than merely correlated with it. EDITGENE provides the engineered cell models and screening services that make such causal experiments practical.
Contact EDITGENE today to design your custom CRISPR model for HLA-B specific inhibitory MHC class I receptor activity research.
Frequently Asked Questions About HLA-B specific inhibitory MHC class I receptor activity
What is HLA-B specific inhibitory MHC class I receptor activity?
It is the molecular function defined by GO:0030109, in which a receptor combines with an HLA-B class I molecule and delivers a signal that inhibits lymphocyte activation.
What genes are involved in HLA-B specific inhibitory MHC class I receptor activity?
Key genes include HLA-B as the ligand and inhibitory receptors such as LILRB1, LILRB2 and KIR3DL family members, with B2M required for class I surface expression.
Which receptors recognize HLA-B and inhibit lymphocytes?
Leukocyte Ig-like receptors such as LILRB1/ILT2 and LILRB2/ILT4, and inhibitory killer cell Ig-like receptors, recognize MHC class I and inhibit NK and T cells.
How does HLA-B allelic variation affect inhibitory receptor binding?
HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding, so different HLA-B variants engage receptors with different strengths.
What is the role of Bw4 and Bw6 motifs in this activity?
Bw4 and Bw6 motifs are determinants of MHC class I recognition by killer cell Ig-like receptors, and even macaque KIR3DL shows degenerate recognition of both motifs.
Why is HLA-B specific inhibitory signaling important in cancer?
Inhibitory MHC class I receptors on NK and T cells can limit lymphocyte activation, so this axis is a target for immunotherapy strategies that restore killing.
Can drugs disrupt HLA-B specific inhibitory receptor signaling?
Yes, amoxicillin conjugates to HLA class I molecules and interferes with signaling through the ILT2/LIR-1/CD85j inhibitory receptor.
What model systems are used to study GO:0030109?
Researchers use receptor-ligand binding assays, NK and T cell functional assays, CRISPR knockout and knock-in cells, and HLA-B transgenic mice such as HLA-B*0702 models.
Do intracellular residues of MHC class I affect receptor recognition?
Yes, intracellular cysteine residues in the tail of MHC class I proteins are crucial for extracellular recognition by leukocyte Ig-like receptor 1.
How can CRISPR help study HLA-B specific inhibitory MHC class I receptor activity?
CRISPR knockout, point mutation, knock-in and overexpression allow causal testing of HLA-B alleles and inhibitory receptors in lymphocyte models.
Conclusion
GO:0030109 captures a precise and clinically relevant molecular function: inhibitory recognition of HLA-B by lymphocyte receptors. Its structural rules are written in HLA-B allelic sequence and conformation, and its functional consequences are measured in NK and T cell activation thresholds. From drug hypersensitivity to cancer immunotherapy and transplantation, this activity helps explain why individuals differ in immune responsiveness. CRISPR-based knockout, point-mutation, knock-in and overexpression models now make it possible to test these mechanisms causally rather than descriptively.
References
- 1. Jones DC et al.. 2011. HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding.. J Immunol 186(5):2990-7 PMID: 21270408
- 2. Moretta A et al.. 1997. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes.. Immunol Rev 155:105-17 PMID: 9059886
- 3. Morel E et al.. 2007. Amoxicillin conjugates to HLA class I molecules and interferes with signalling through the ILT2/LIR-1/CD85j inhibitory receptor.. Allergy 62(2):190-6 PMID: 17298429
- 4. Deng Z et al.. 2021. Adaptive Admixture of HLA Class I Allotypes Enhanced Genetically Determined Strength of Natural Killer Cells in East Asians.. Mol Biol Evol 38(6):2582-2596 PMID: 33616658
- 5. Maloveste SM et al.. 2012. Degenerate recognition of MHC class I molecules with Bw4 and Bw6 motifs by a killer cell Ig-like receptor 3DL expressed by macaque NK cells.. J Immunol 189(9):4338-48 PMID: 23041569
- 6. Alexander J et al.. 2003. Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes.. Hum Immunol 64(2):211-23 PMID: 12559623
- 7. Gruda R et al.. 2007. Intracellular cysteine residues in the tail of MHC class I proteins are crucial for extracellular recognition by leukocyte Ig-like receptor 1.. J Immunol 179(6):3655-61 PMID: 17785801
- 8. Moretta L et al.. 1996. The molecular basis of natural killer (NK) cell recognition and function.. J Clin Immunol 16(5):243-53 PMID: 8886992
